Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial ribosomal protein L2 (MRPL2) is a nuclear-encoded protein that forms a part of the 39S large subunit of the mitochondrial ribosome in mammalian cells[1][4][9]. MRPL2 is involved in mitochondrial protein synthesis by facilitating the translation of mitochondrial DNA-encoded proteins, essential for oxidative phosphorylation and energy metabolism[1][3][4][6][9]. It functions as a structural constituent of the mitochondrial ribosome and is involved in RNA binding as a part of its role in translation[3][5]. Disruption in MRPL2 or the mitochondrial ribosome can affect mitochondrial function, which has downstream implications for cellular energy production, but MRPL2 is not a common direct target for therapeutic intervention or drug development[3][6][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial ribosomal protein L2 (MRPL2).